The cystine-glutamate antiporter xCT has been previously shown to contribute to the proinflammatory phenotype of primary microglial cells and to be involved in amyotrophic lateral sclerosis (ALS)- and Alzheimer’s disease-related pathogenesis [77, 78]. This evidence concerns the gene SLC7A11 and amyotrophic lateral sclerosis.